Oncolytics reports positive Phase II data for head and neck anticancer
This article was originally published in Scrip
Executive Summary
Canadian firm, Oncolytics Biotech, has reported positive Phase II results for its anticancer therapeutic, Reolysin, when used in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.